Watchlist Price Alert

Candel Therapeutics Inc. (CADL)

NASDAQ: CADL · Real-Time Price · USD

4.90

-0.13 (-2.58%)

At close: Jun 27, 2025, 3:59 PM

4.90

0.02%

After-hours: Jun 27, 2025, 04:34 PM EDT

-2.58% (1D)

Bid	4.7
Market Cap	245.45M
Revenue (ttm)	n/a
Net Income (ttm)	-39.58M
EPS (ttm)	-1.33
PE Ratio (ttm)	-3.68
Forward PE	-3.91
Analyst	Buy

Ask	5.1
Volume	705,832
Avg. Volume (20D)	953,727
Open	5.01
Previous Close	5.03
Day's Range	4.85 - 5.11
52-Week Range	3.79 - 14.60
Beta	-0.87

About CADL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CADL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CADL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+6.07%

Shares of Candel Therapeutics are trading higheraf... Unlock content with Pro Subscription

2 months ago

+0.42%

Candel Therapeutics shares are trading higher after the company announced the oral pretension of its Phase 3 CAN-2409 results in localized prostate cancer at ASCO 2025.

News

4 days ago · zacks.com

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 days ago · proactiveinvestors.com

Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations

Candel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercializ...

6 days ago · proactiveinvestors.com

Candel Therapeutics names Charles Schoch as CFO after interim tenure

Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Charles Schoch as its chief financial officer. Schoch had served as interim CFO since January 2024 and is being elevated to the pe...

3 weeks ago · proactiveinvestors.com

Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board

Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.

3 weeks ago · zacks.com

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 285.3% in Candel Therapeutics (CADL). While the effectiveness of this highly sought-after metric is questionabl...

1 month ago · zacks.com

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.

1 month ago · proactiveinvestors.com

Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy

Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, C...

1 month ago · proactiveinvestors.com

Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025

Candel Therapeutics Inc (NASDAQ:CADL) announced that it will present results from its positive Phase 3 trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer at the 202...